{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:48:40Z","timestamp":1793278120620,"version":"4.5.0"},"reference-count":28,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hemophilia is treated by IV replacement therapy with Factor VIII (FVIII) or Factor IX (FIX), either on demand to resolve bleeding, or as prophylaxis. Improved treatment may be provided by drugs designed for subcutaneous and less frequent administration with a reduced risk of inhibitor formation. Tissue factor pathway inhibitor (TFPI) down-regulates the initiation of coagulation by inhibition of Factor VIIa (FVIIa)\/tissue factor\/Factor Xa (FVIIa\/TF\/FXa). Blockage of TFPI inhibition may facilitate thrombin generation in a hemophilic setting. A high-affinity (KD = 25pM) mAb, mAb 2021, against TFPI was investigated. Binding of mAb 2021 to TFPI effectively prevented inhibition of FVIIa\/TF\/FXa and improved clot formation in hemophilia blood and plasma. The binding epitope on the Kunitz-type protease inhibitor domain 2 of TFPI was mapped by crystallography, and showed an extensive overlap with the FXa contact region highlighting a structural basis for its mechanism of action. In a rabbit hemophilia model, an intravenous or subcutaneous dose significantly reduced cuticle bleeding. mAb 2021 showed an effect comparable with that of rFVIIa. Cuticle bleeding in the model was reduced for at least 7 days by a single intravenous dose of mAb 2021. This study suggests that neutralization of TFPI by mAb 2021 may constitute a novel treatment option in hemophilia.<\/jats:p>","DOI":"10.1182\/blood-2012-01-401620","type":"journal-article","created":{"date-parts":[[2012,5,5]],"date-time":"2012-05-05T20:14:57Z","timestamp":1336248897000},"page":"5871-5878","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":149,"title":["Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model"],"prefix":"10.1182","volume":"119","author":[{"given":"Ida","family":"Hilden","sequence":"first","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lauritzen","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit Binow","family":"S\u00f8rensen","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes Thorn","family":"Clausen","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Jespersgaard","sequence":"additional","affiliation":[{"name":"CMC Supply, Novo Nordisk, Maaloev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit Olsen","family":"Krogh","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Neil","family":"Bowler","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Breinholt","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Gruhler","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Anders","family":"Svensson","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle Heibroch","family":"Petersen","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Christian","family":"Petersen","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer W.","family":"Balling","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Hansen","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Brunsgaard","family":"Hermit","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Egebjerg","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Friederichsen","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Ezban","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Erik","family":"Bj\u00f8rn","sequence":"additional","affiliation":[{"name":"Biopharmaceuticals Research Unit and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"19","key":"2019111809422092900_B1","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/archinternmed.2010.367","article-title":"Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review.","volume":"170","author":"Iorio","year":"2010","journal-title":"Arch Intern Med"},{"issue":"4","key":"2019111809422092900_B2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0049-3848(08)70027-6","article-title":"Extending half-life in coagulation factors: where do we stand?","volume":"122","author":"Lillicrap","year":"2008","journal-title":"Thromb Res"},{"issue":"4","key":"2019111809422092900_B3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1055\/s-0038-1646439","article-title":"Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.","volume":"66","author":"Nordfang","year":"1991","journal-title":"Thromb Haemost"},{"issue":"5","key":"2019111809422092900_B4","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00001721-199507000-00004","article-title":"Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A.","volume":"6","author":"Erhardtsen","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"5","key":"2019111809422092900_B5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1538-7836.2006.01947.x","article-title":"Thrombin generation in factor VIII-depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitor.","volume":"4","author":"Fritsch","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2019111809422092900_B6","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2008-06-162453","article-title":"Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency.","volume":"112","author":"Duckers","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2019111809422092900_B7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood-2007-07-098913","article-title":"Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A.","volume":"111","author":"Prasad","year":"2008","journal-title":"Blood"},{"issue":"20","key":"2019111809422092900_B8","doi-asserted-by":"crossref","first-page":"5514","DOI":"10.1182\/blood-2010-10-311936","article-title":"Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.","volume":"117","author":"Waters","year":"2011","journal-title":"Blood"},{"key":"2019111809422092900_B9","doi-asserted-by":"crossref","first-page":"8869","DOI":"10.1073\/pnas.87.22.8869","article-title":"Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis.","volume":"87","author":"Bajaj","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2019111809422092900_B10","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1182\/blood.V79.12.3219.3219","article-title":"Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators.","volume":"79","author":"Ameri","year":"1992","journal-title":"Blood"},{"issue":"12","key":"2019111809422092900_B11","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1182\/blood.V97.12.3721","article-title":"Regulation of monocyte procoagulant activity in acute myocardial infarction: role of tissue factor and tissue factor pathway inhibitor-1.","volume":"97","author":"Ott","year":"2001","journal-title":"Blood"},{"issue":"6","key":"2019111809422092900_B12","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V72.6.2020.2020","article-title":"Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor.","volume":"72","author":"Novotny","year":"1988","journal-title":"Blood"},{"issue":"31","key":"2019111809422092900_B13","doi-asserted-by":"crossref","first-page":"18832","DOI":"10.1016\/S0021-9258(18)51542-8","article-title":"Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.","volume":"264","author":"Novotny","year":"1989","journal-title":"J Biol Chem"},{"issue":"4","key":"2019111809422092900_B14","first-page":"551","article-title":"Heterogeneity of plasma tissue factor pathway inhibitor.","volume":"5","author":"Broze","year":"1994","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"8","key":"2019111809422092900_B15","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1074\/jbc.273.8.4378","article-title":"Regulation of extrinsic pathway factor Xa formation by tissue factor pathway inhibitor.","volume":"273","author":"Baugh","year":"1998","journal-title":"J Biol Chem"},{"issue":"5","key":"2019111809422092900_B16","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1055\/s-0038-1648489","article-title":"Effect of leukocyte proteinases on tissue factor pathway inhibitor.","volume":"67","author":"Petersen","year":"1992","journal-title":"Thromb Haemost"},{"issue":"18","key":"2019111809422092900_B17","doi-asserted-by":"crossref","first-page":"13344","DOI":"10.1016\/S0021-9258(19)38657-0","article-title":"Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae.","volume":"268","author":"Petersen","year":"1993","journal-title":"J Biol Chem"},{"issue":"2","key":"2019111809422092900_B18","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1093\/nar\/30.2.e9","article-title":"High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells.","volume":"30","author":"Durocher","year":"2002","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2019111809422092900_B19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1055\/s-0038-1642658","article-title":"Tissue factor pathway inhibitor.","volume":"74","author":"Broze","year":"1995","journal-title":"Thromb Haemost"},{"issue":"2","key":"2019111809422092900_B20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/ATVBAHA.107.141606","article-title":"The haemostatic role of tissue factor pathway inhibitor.","volume":"28","author":"Crawley","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2019111809422092900_B21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/path.1871","article-title":"Tissue factor pathway inhibitor: structure, biology and involvement in disease.","volume":"208","author":"Lwaleed","year":"2006","journal-title":"J Pathol"},{"issue":"12","key":"2019111809422092900_B22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1161\/01.RES.83.12.1264","article-title":"Expression of tissue factor pathway inhibitor in vascular smooth muscle cells and its regulation by growth factors.","volume":"83","author":"Caplice","year":"1998","journal-title":"Circ Res"},{"issue":"5","key":"2019111809422092900_B23","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1055\/s-0037-1616070","article-title":"Production of tissue factor pathway inhibitor in cardiomyocytes and its upregulation by interleukin-1.","volume":"86","author":"Kereveur","year":"2001","journal-title":"Thromb Haemost"},{"issue":"1","key":"2019111809422092900_B24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.transci.2007.12.001","article-title":"Expression of tissue factor pathway inhibitor by endothelial cells and platelets.","volume":"38","author":"Maroney","year":"2008","journal-title":"Transfus Apher Sci"},{"issue":"2","key":"2019111809422092900_B25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.ATV.19.2.309","article-title":"Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages: relationship to tissue factor induction by cholesterol and oxidized LDL.","volume":"19","author":"Petit","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2019111809422092900_B26","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.thromres.2010.01.038","article-title":"Alternatively spliced isoforms of tissue factor pathway inhibitor.","volume":"125","author":"Maroney","year":"2010","journal-title":"Thromb Res"},{"issue":"3","key":"2019111809422092900_B27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1006\/jmbi.1997.1029","article-title":"The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa.","volume":"269","author":"Burgering","year":"1997","journal-title":"J Mol Biol"},{"issue":"1","key":"2019111809422092900_B28","first-page":"194","article-title":"A glycoPEGylated long acting rFVIIa reduces bleeding in hemophilic rabbits [abstract].","volume":"7","author":"Lauritzen","year":"2009","journal-title":"J Thromb Haemost"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/24\/5871\/1497304\/zh802412005871.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/24\/5871\/1497304\/zh802412005871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T19:46:13Z","timestamp":1642189573000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/24\/5871\/30325\/Hemostatic-effect-of-a-monoclonal-antibody-mAb"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,14]]},"references-count":28,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-01-401620","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,14]]}}}